Summary:
A total of 415 leukaphereses in 201 patients stimulated with growth factor (GF; n ¼ 119) or chemotherapy-GF (n ¼ 296) were studied to determine CD34 þ cell collection efficiency (CE). The pre-apheresis leukocyte count was 1-93 Â 10 9 /l (median 20), and peripheral blood CD34 count (PBCD34) was 1-1104/ll (median 19). The total number of CD34 þ cells collected was 4-6531 Â 10 6 (median 151); corresponding to 0.1-111.4 Â 10 6 (median 2.3) per kg. There was strong correlation between PBCD34 and the number of CD34 þ cells collected (r ¼ 0.9; Po0.0001). CE was 7-145% (median 46). On multiple regression analysis, a higher leukocyte count (Po0.0001) was the most important predictor of lower CE. CE with leukocytes o20 was 7-145% (median 53%) compared to 10-132% (median 40%) with leukocyte X20 (Po0.0001). In all, 61% of the apheresis procedures performed after chemotherapy-GF occurred when leukocytes were o20 compared to 21% of those performed after GF alone (Po0.0001). We conclude that mobilizing patients with the combination of chemotherapy and GF rather than GF alone leads to leukapheresis being performed when the leukocyte count is low -in a range that results in optimum CD34 þ cell CE. Autologous stem cells should be mobilized with chemotherapy-GF rather than GF alone whenever possible. Autologous hematopoietic stem cells are mobilized into the blood with chemotherapy followed by growth factor (GF) or GF alone. 1 Stimulation with GF alone results in a predictable collection schedule, with apheresis usually commencing on the fourth or fifth day of GF administration -when there is significant leukocytosis ranging from 10 to 100 Â 10 9 /l. Chemotherapy-GF mobilization is less predictable because of variable marrow suppression and recovery patterns, and apheresis usually commences 12-25 days after chemotherapy is started -when the leukocyte count is just beginning to recover from the nadir. There is often a specific reason to choose one mobilization technique over another such as study protocol, activity of the underlying disease, and baseline bone marrow function (blood counts). However, frequently, this is not the case and an arbitrary choice has to be made between GF alone and chemotherapy-GF for mobilization. 1 Collection efficiency (CE) is a reflection of the proportion of cells passing through a cell separator that is harvested. The concept of CE is relevant clinically because higher CD34 þ cell CE results in a greater number of progenitor cells being collected per procedure -which reduces the number of procedures (and time) required to meet the target cell yield and therefore the cost. We have previously shown that the use of a Cobe Spectra cell separator for leukapheresis results in a better CE than Fenwal CS 3000 Plus, 2 and the hematocrit does not affect CE. 3 SarkodeeAdoo et al 4 found that female sex, the blood volume processed, and the pre-apheresis peripheral blood CD34 þ cell count (PBCD34) affected CD34 þ cell CE adversely.
Our previous study 2 detected a modest negative correlation between the total leukocyte count and the CD34 þ CE with the CS 3000 machine but not with the Spectra. However, the number of apheresis procedures performed on the Spectra was small (n ¼ 61). We decided to explore the relationship between leukocyte counts and CD34 þ CE for the Spectra further in a significantly larger number of procedures (n ¼ 415). (1) availability of pre-apheresis PBCD34 on the day of apheresis (not done routinely prior to all apheresis procedures), and (2) pre-apheresis PBCD34 X0.02% (elimination of procedures with lower % PBCD34 to reduce variability and magnification of calculation errors). Thus, not all apheresis procedures done during the specified time period were studied, and for patients who were studied not all leukapheresis procedures performed were necessarily studied. However, all procedures fulfilling the inclusion criteria were studied. It should be noted that this incompleteness does not affect this analysis which focuses on technical aspects of apheresis.
Patients and methods
Patients mobilized with GF alone started GF on day 1 and leukapheresis on day 4. Those mobilized with chemotherapy-GF started leukapheresis upon leukocyte recovery from the nadir, usually when the PBCD34 exceeded 5 per ml. Table 1 shows patient characteristics. All experimental or research protocols were approved by the Institutional Review Board, as was this retrospective analysis.
Apheresis technique
All patients had rigid or semi-rigid 2-lumen in-dwelling catheters inserted for apheresis. All procedures were performed on Cobe Spectra cell separators (Gambro BCT, Lakewood, CO, USA) maintained and serviced according to the manufacturer's recommendations. The blood flow rate used for apheresis was 70-100 ml/min. A majority of the procedures were performed using the mononuclear cell collection protocol (Version 4.7). The blood volume processed was 15 or 20 l over approximately 3-5 h in almost all patients (10 l in eight procedures; grouped with 15 l procedures for all analyses). All patients provided informed consent for the procedure.
Flow cytometry
CD34 þ cells were enumerated using standard techniques 5 on the peripheral blood prior to leukapheresis and on the apheresis product prior to processing and cryopreservation.
Data analysis and statistical methods
The CD34 þ cell CE was the proportion (expressed as %) of the total CD34 þ cells processed (ie passing through the cell separator) that was harvested, and was calculated as follows: {Total number of CD34 þ cells collected Â 10 À4 }/ {Absolute peripheral blood CD34 þ cell count per ml Â Blood volume processed (l)}.
Regression analysis was used to assess correlation between the pre-apheresis leukocyte count and the total number of CD34 þ cells collected, as well as that between the pre-apheresis total leukocyte count and the total number of CD34 þ cells collected. Regression analysis was also employed to assess the correlation between the leukocyte count and CE, and the peripheral blood CD34 þ cell count and CE. The w 2 test was used to compare categoric variables and the Wilcoxon rank-sum test was used to compare continuous variables. Finally, multivariate regression analysis was used to determine which of the following factors influenced CE independently: leukocyte count, platelet count, hematocrit, PBCD34, age, sex, weight, diagnosis, mobilization technique, and the blood volume processed. It should be noted that biological variables related to the disease, its therapy, the type of mobilization chemotherapy used, and doses of growth factors used are relevant to mobilization rather than collection and CE -and therefore were not analyzed.
Results
The total number of CD34 þ cells harvested per procedure was 4-6531 Â 10 6 (median 151), corresponding to 0.1-111.4 Â 10 6 /kg ideal body weight (median 2.3). As expected, there was very strong correlation between PBCD34 and the number of CD34 þ cells collected (r ¼ 0.9; Po0.0001).
Collection efficiency
The CD34 þ cell CE was 7-145% (median 46). There was no significant correlation between CE and age (r ¼ 0.01; P ¼ 0.84), ideal body weight (r ¼ 0.01; P ¼ 0.84), and Hct (r ¼ 0.04; P ¼ 0.25). A modest negative correlation was found between pre-apheresis PBCD34 and CE (r ¼ À0.18; P ¼ 0.0002; Figure 1) , and a stronger negative relationship between the pre-apheresis leukocyte count and CE (r ¼ À0.28; Po0.0001; Figure 2) . CE for the 202 procedures where 10-15 l blood was processed was 10-145% (median 48) compared with 7-143% (median 43) for the 213 procedure where 20 l blood was processed (P ¼ 0.15). CE for the 271 procedures done in males was 7-145% (median 45) compared with 12-118% (median 47) for the 144 procedures in females (P ¼ 0.98). Table 3 explores the relationship shown in Table 2 further. This illustrates that for a given range of leukocyte counts, the mobilization technique made no difference to the CE. The total number of CD34 þ cell collected -the ultimate measure of success of leukapheresis -was quite similar for chemotherapy-GF patients irrespective of leukocyte count and GF-treated patients with leukocytes X20 -and was much higher than that for GF-treated patients with leukocytes o20. Figure 3 shows the effect of the mobilization technique on leukocyte counts and CE graphically. Importantly, however, there was a close relationship between the leukocyte count and the mobilization technique: 182 of 296 (61%) chemotherapy-GF harvests occurred with a total leukocyte count of o20 Â 10 9 /l, compared with 25 of 119 (21%) harvests with GF alone (Po0.0001). Thus, harvests performed after chemotherapy-GF were almost three times likelier than harvests performed after GF alone to have been done when the leukocyte count was in a range that resulted in a higher CE.
Factors affecting CE
On multivariate regression analysis, higher leukocyte counts (continuous variable; Po0.0001), higher PBCD34 (continuous variable; P ¼ 0.003), and a higher processed blood volume (categoric variable; P ¼ 0.02) were associated with lower CE.
Discussion
Our analysis shows that CE with a total leukocyte count of o20 was 7-145% (median 53%) compared to 10-132% (median 40%) with a total leukocyte count of X20, suggesting that a low leukocyte count is optimal for apheresis in terms of maximizing CE. The relationship Figure 3 The effect of the stem cell mobilization technique on leukocyte count and CE (for details, see Tables 2 and 3 ).
between stem cell mobilization technique and CD34 þ cell CE has not been explored previously. We show that while there is no direct relationship between the two, there is an indirect relationship: a much greater proportion of harvests performed after chemotherapy-GF take place when the total leukocyte count is o20 Â 10 9 /l -and thus when the CE is better. As the leukocyte count increases, CE falls -irrespective of the mobilization technique. This suggests that unless there is a compelling reason to collect stem cells after mobilization with GF alone, the combination of chemotherapy and GF is preferable for mobilization as it permits collection to occur with a lower leukocyte count maximizing CE.
When apheresis is performed after chemotherapy-GF, the PBCD34 level usually reaches a threshold suitable for apheresis when the total leukocyte count is in the 1-5 Â 10 9 /l range. While the per cent PBCD34 tends to fall as hematologic recovery continues, the absolute PBCD34 does not fall -and may even rise -as the extent of leukocytosis increases. The falling CE is compensated by the increasing PBCD34 and the total quantity of CD34 þ cells collected is not compromised. This is shown clearly in Table 3 .
Overall, the CE of 46% seen here is in keeping with that reported by others 4, 6, 7 and by us in a smaller number of patients. 2, 3 Age, ideal body weight, and underlying disease did not correlate with CE. While it has been reported elsewhere that female sex favorably impacts CE, 4 our results do not indicate any difference in CE between men and women.
In many patients, there are overriding reasons to choose GF alone or chemotherapy-GF for mobilization. For example, a patient with active disease may be better off with chemotherapy-GF particularly with marrow involvement. A patient with a history of extensive prior cytotoxic chemotherapy may fare better with GF alone. However, in patients in whom such factors do not exist, the use of chemotherapy-GF will allow apheresis to occur in a manner that is technically more favorable.
We conclude that mobilizing patients with the combination of chemotherapy and GF rather than GF alone is likely to lead to leukapheresis being performed when the WBC count is in a range that results in optimum CD34 þ cell CE. Autologous stem cells should be mobilized with chemotherapy-GF rather than GF alone if this is clinically feasible to utilize the process of apheresis more favorably. Table 3 The effect of mobilization technique and the extent of leukocytosis on CD34+ cell counts and collection efficiency 
